Clinicohematological parameters and outcomes in a cohort of chronic lymphocytic leukemia patients with Deletion 17p from Pakistan.
- Author:
Rafia MAHMOOD
1
;
Saleem Ahmed KHAN
;
Chaudhry ALTAF
;
Hamid Saeed MALIK
;
Muhammad Tahir KHADIM
Author Information
- Publication Type:Original Article
- Keywords: Chronic lymphocytic leukemia; Fluorescent in situ hybridization; Event-free survival; Overall survival
- MeSH: Arm; Cohort Studies*; Cytogenetic Analysis; Cytogenetics; Diagnosis; Disease-Free Survival; Education; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell*; Male; Observational Study; Pakistan*; Pathology; Population Characteristics; Prognosis; Prospective Studies; Survival Rate
- From:Blood Research 2018;53(4):276-280
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Chronic lymphocytic leukemia (CLL) exhibits profound heterogeneity in its clinical course. Its clinicohematological and cytogenetic features play a significant role in determining the clinical course and in predicting the treatment response and prognosis. In this context, 17p deletion is known to predict a poor prognosis, as these cases are refractory to conventional therapy. This study aimed to evaluate the clinicohematological characteristics, outcomes, and prognostic factors among CLL patients with and without del 17p in Pakistan. METHODS: This prospective observational study was conducted at the Department of Haematology, Armed Forces Institute of Pathology (Rawalpindi, Pakistan) between January 2013 and December 2017. Patients were diagnosed based on the International Workshop on Chronic Lymphocytic Leukaemia IWCLL criteria, their clinicohematological parameters were recorded, and cytogenetic analyses were performed. The time from diagnosis to treatment and the 2-year overall survival rate were also evaluated. RESULTS: We evaluated 130 CLL cases, including 24 patients (18.5%) with del 17p, who included 18 men (75%) and 6 women (25%). The median age was 68 years. Binet stage C was detected at the presentation in 16 patients (67%). Treatment was administered to 14 patients (70%) at a median interval of 11 months (range, 0–28 mo) after diagnosis. The overall response rate was 64.3%, the median event-free survival was 9 months (range, 1–23 mo), and the 2-year overall survival rate was 65%. CONCLUSION: Del 17p is relatively common in Pakistan, and patients harboring this deletion had poor treatment response and survival outcomes.
